Loading clinical trials...
Loading clinical trials...
Showing 1-20 of 388 trials
NCT07300436
This is Single-center, randomized, open-label, single-dose, two-period crossover study design. The goal is to preliminary evaluate the PK comparability of TJ101 injection before and after CMC change following a single subcutaneous injection of 1.2 mg/kg in healthy male subjects in China, and to assess whether the two formulations are bio equivalent.
NCT07535905
Androgen deprivation therapy (ADT) is a cornerstone therapy in the treatment of curable prostate cancer (PCa). However, ADT often leads to a protracted testosterone recovery period in most men or absence of complete recovery in 10-25% of cases. The hypogonadal state has significant psychosocial and physical side effects. Therefore, limiting ADT effect's duration beyond the prescribed castration period is very compelling to patients and providers alike. Tamoxifen, a well-established selective estrogen receptor modulator, offers a novel and cost-effective approach to accelerate testosterone recovery in men with secondary hypogonadism. This project addresses a critical gap in global cancer care by evaluating Tamoxifen as a viable solution for reducing the burden of delayed testosterone recovery and its associated side effects, particularly in resource-limited settings.
NCT07596511
The goal of this study is to learn if low-dose caffeinated coffee improves repeated sprint performance and affects energy system contributions in combat sports athletes. The main questions it aims to answer are: * Does low-dose caffeinated coffee (1.5 or 3 mg·kg-¹) improve peak power, mean power, and fatigue index during repeated sprint tests? * What physiological responses (heart rate, blood lactate, perceived exertion, and energy system contributions) do participants have when consuming caffeinated coffee? Researchers compared caffeinated coffee at two doses (1.5 and 3 mg·kg-¹ body mass) to a placebo (decaffeinated coffee of identical taste and appearance) to see if low
NCT07584772
A prospective, uncontrolled, non-pharmacological interventional study conducted on men with functional or borderline hypogonadism, aimed at evaluating, after 3 months of supplementation with D-Chiro-inositol, changes in hormonal profile and sexual function.
NCT07036458
To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects
NCT07546435
Several international studies indicate that men with reduced semen quality often feel overlooked in the context of fertility treatment. Men who undergo fertility treatment due to their own infertility, exhibit increased concern and experience more negative emotions such as loss, stigmatization, and low self-esteem - more so than men undergoing fertility treatment for other reasons. Since 2008, there has been limited research on the experiences of male patients with infertility in Denmark. Furthermore, there is generally very little knowledge regarding the testosterone levels (hypogonadism) of male infertile patients and its association with quality of life. Thus, there is a lack of updated insight into how infertile men experience their situation today. Additionally, the present study finds it relevant to examine whether men's needs and experiences in interactions with health professionals have changed over the past 15 years.
NCT04452305
Spermatogonial stem cell transplantation through ultrasound guided rete testis injection and testicular tissue grafting will be performed for participants who have frozen testicular tissue prior to gonadotoxic therapy. The purpose of this study is to test the safety and feasibility of these transplant technologies and restore fertility for these participants.
NCT07305532
Healthy volunteers aged 18 to 85 will undergo ¹⁹F (perfluoropropane) MRI to support the development of imaging sequences, reconstruction algorithms, and hardware necessary for acquiring high-spatial resolution lung images. The study will also evaluate signal-to-noise ratio, contrast-to-noise ratio, spatial resolution, scan duration, and pulmonary gas exchange measurements derived from ¹⁹F (perfluoropropane) MRI.
NCT03162627
This study has 2 phases: Phase 1 (dose escalation) and Phase 2 (dose expansion). The goal of Phase 1 of this clinical research study is to find the highest tolerable dose combination of selumetinib and olaparib that can be given to patients who have solid tumors that are advanced or recurrent (has returned after treatment). The goal of Phase 2 is to learn if the highest tolerable dose combination found in Phase 1 can help to control advanced or recurrent solid tumors. The safety of the study drug combination will also be studied in both parts. This is an investigational study. Selumetinib is not FDA approved or commercially available. It is currently being used for research purposes only. Olaparib is FDA approved and commercially available for the treatment of ovarian cancer that has a certain type of genetic mutation (change). It is considered investigational to use selumetinib in combination with olaparib to treat advanced or recurrent cancer. The study doctor can explain how the study drugs are designed to work. Up to 90 participants will be enrolled in this study. All will take part at MD Anderson.
NCT07367958
This is phase 1 study to Compare the Pharmacokinetics, Safety and Immunogenicity of the Auto-injector and Pre-filled syringe of CT-P52 in Healthy Male Subjects.
NCT06190899
This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with mCRPC.
NCT07299955
This phase I study is to compare the pharmacokinetics (PK), immunogenicity, safety, and tolerability of Bmab3000 (test) and Herceptin Hylecta (reference) after a single subcutaneous (s.c.) dose in healthy male volunteers.
NCT07395583
Football is a sport with a high risk of injury, and hamstring muscle injuries are among the most common problems faced by players. These injuries can reduce a player's performance, cause time away from training and matches, and place a burden on medical teams and clubs. Many training programs recommend eccentric hamstring exercises to prevent these injuries, but there is limited evidence comparing eccentric exercises with concentric exercises or a combination of both, especially in elite male football players. The purpose of this study is to compare the long-term effects of three different hamstring strengthening programs-eccentric training, concentric training, and a combination of both-on preventing non-contact hamstring injuries in elite male footballers. Each training program will last for three months, and the players will be followed for a total period of 12 months. The study will look at how these programs affect hamstring injury prevention, muscle strength and performance, flexibility, recurrence of injuries, and players' psychological satisfaction. The study is based on the following expectations: A three-month eccentric hamstring strengthening program will lead to long-term improvements in reducing hamstring injuries, improving muscle performance and flexibility, lowering injury recurrence, and increasing psychological satisfaction over a 12-month period. A three-month concentric hamstring strengthening program will also result in long-term improvements in injury prevention, muscle performance, flexibility, injury recurrence, and psychological satisfaction. A combined program of eccentric and concentric hamstring strengthening over three months will produce significant long-term benefits in injury prevention, muscle performance, flexibility, injury recurrence, and psychological satisfaction. There will be clear differences in outcomes between the eccentric, concentric, combined, and control groups over the 12-month follow-up period. Participants will be divided into four groups (A, B, C, and D) based on the type of training they receive. The study will include young male professional football players aged 18 to 30 years from the UAE who are citizens or permanent residents. All participants must speak English, have at least one year of football playing experience, and must not have had any hamstring injury in the past six months. Players who are interested in participating and provide written informed consent will be included. Players will be excluded if they have had a hamstring injury in the last six months, are female, are under 18 or over 30 years old, have restrictions in knee movement, have undergone previous hamstring surgery, are currently enrolled in another official rehabilitation program, or do not agree to participate in the study. Group A participants will perform eccentric hamstring exercises, including Nordic hamstring curls, dumbbell stiff-leg deadlifts, and barbell Romanian deadlifts. Group B participants will perform concentric hamstring exercises such as seated leg curls, lying leg curls, and prone hamstring curls using resistance bands. Group C participants will perform a combination of both eccentric and concentric hamstring exercises. Group D participants will continue with their usual football training only and will not perform any additional hamstring-specific exercises. Before each training session, all participants in Groups A, B, and C will complete a 10-minute warm-up, consisting of five minutes of cycling, three minutes of stretching, and two minutes of rope jumping. Each training session will last at least 30 minutes. The exercise groups will complete three additional training sessions per week alongside their regular football training for a total of 12 weeks. The results of this study will help determine which type of hamstring training program is most effective in preventing non-contact hamstring injuries and improving physical and psychological outcomes in elite male football players.
NCT07450521
A randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, and PK of MTX-463 when administered via SC injection in healthy adult males.
NCT03420963
This phase I trial studies the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells (donor natural killer \[NK\] cells) and how well they work when given together with cyclophosphamide and etoposide in treating children and young adults with solid tumors that have come back (relapsed) or that do not respond to treatment (refractory). NK cells, white blood cells important to the immune system, are donated/collected from cord blood collected at birth from healthy babies and grown in the lab. Drugs used in chemotherapy, such as cyclophosphamide and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving NK cells together with cyclophosphamide and etoposide may work better in treating children and young adults with solid tumors.
NCT01511588
Background: \- The body produces gonadotropin-releasing hormone (GnRH) about every 2 hours. GnRH travels through the bloodstream to the pituitary gland, where it stimulates the gland to produce hormones called gonadotropins. These hormones stimulate the testicles or ovaries. The testicles produce testosterone and develop sperm. The ovaries produce estrogen and prepare for ovulation. Normal estrogen and testosterone levels are required for puberty. Some people, however, have either low levels or total lack of GnRH. This can cause problems with puberty and fertility. Researchers want to study people with low or no GnRH to better understand how it affects puberty and fertility. Objectives: \- To study disorders of GnRH production. Eligibility: * Adult men and women at least 18 years of age with low or no gonadotropin levels. * Adolescents between 14 and 18 years of age with low or no gonadotropin levels. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. * Participants will have tests to look at their hormone levels. Blood samples may be collected after taking different drugs, including insulin and cortisone. A 24-hour urine sample will be collected. * Participants will have imaging studies to look at bone and brain development. They will also have ultrasounds of the kidneys, abdomen, and reproductive organs. * Tests of smell and hearing will be used to look for abnormalities in these senses.
NCT07460726
This study looks at how combined radiation and hormone therapy affects sexual function in men with a specific type of prostate cancer, before and after treatment.
NCT07454265
The study aimed to evaluate the effects of short-term broccoli powder supplementation on metabolically demanding exercise performance, muscle power, and blood lactate recovery. It also investigated broccoli powder-derived sulforaphane bioavailability and its effects in attenuating exercise-induced oxidative stress. Seventeen healthy males (age 23.8 ± 4.9 years, height 182.3 ± 6.1 cm, weight 80.0 ± 12.8 kg), in a double-blind crossover design, three weeks apart, consumed ten standard doses of either broccoli powder or spinach powder as a placebo over a period of 2 weeks. They then performed a maximal progressive cycling task with concomitant analysis of expired gas composition. Plasma malondialdehyde (MDA) level was measured before and 60 min after the completion of the task, and blood lactate and muscle power (counter-movement vertical jump (CMJ) performance) were measured before and up to 60 min after exercise.
NCT05294588
This is a double-blind randomized controlled trial to test whether the group B meningitis vaccine 4 component Neisseria meningitidis serogroup B vaccine (BEXSEROTM) (4C-MenB), trade name Bexsero™), currently approved for use by the United States Food and Drug Administration (FDA) and recommended by the Centers for Disease Control and Prevention (CDC) for protection from Neisseria meningitidis infections, also protects from Neisseria gonorrhoeae infection using controlled human experimental infection to test protection. The information the investigator learn by doing this study may also help to develop a vaccine that protects individuals from having gonorrhea infection. The study population will consist of male participants \> 18 and \< 36 years old, living in central North Carolina, in general good health without a history of 4C-MenB vaccination. Approximately 120-140 participants will be enrolled. Participants will receive 2 doses of vaccine (2 doses of 4C-MenB or 2 comparator vaccines- seasonal influenza and tetanus/diptheria booster) as intramuscular injections, and then one intraurethral challenge with Neisseria gonorrhoeae. Following the challenge, participants will cross-over and receive two doses of vaccines not received prior to challenge (2 doses of 4CMenB or the 2 comparator vaccines- seasonal influenza and tetanus/diptheria booster) All participants receive all vaccinations by the end of the study and all vaccines used in this study are licensed and FDA-approved.
NCT05903859
This is a study of infertility which often occurs in men with spinal cord injury. Most men with spinal cord injury have a normal sperm count but abnormally low sperm motility - which means that the sperm does not swim well. This study will determine if a medicine given by mouth will improve sperm motility in men with spinal cord injuries. The medicine is called probenecid.